Artificial Lung Market Size, Top Share, Demand

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Artificial Lung Market Size Analysis

Global Artificial Lung Market Introduction
By Product Type
1. Introduction
  1. Product Type By Value
2. Extracorporeal Membrane Oxygenation (ECMO) Systems
  1. By Value
3. Paracorporeal Artificial Lungs
  1. By Value
4. Intracorporeal Artificial Lungs
  1. By Value
5. Membrane Oxygenators
  1. By Value
6. Portable Artificial Lungs
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Bridge-to-Transplantation
  1. By Value
3. Bridge-to-Recovery
  1. By Value
4. ECMO-assisted Ventilation
  1. By Value
5. Pulmonary Rehabilitation
  1. By Value
6. Long-term Support for Chronic Lung Diseases
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital-based Procurement
  1. By Value
3. Direct Tenders and Contracts
  1. By Value
4. Group Purchasing Organizations (GPOs)
  1. By Value
5. Online Procurement Platforms (limited role)
  1. By Value
6. Third-party Distributors (emerging in select regions)
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Tertiary Care Hospitals
  1. By Value
3. Transplant Centers
  1. By Value
4. Cardiac and Pulmonary ICUs
  1. By Value
5. Research Institutions and Clinical Trial Sites
  1. By Value
6. Specialty Respiratory Clinics
  1. By Value

North America Market Analysis

Introduction
By Product Type
1. Introduction
  1. Product Type By Value
2. Extracorporeal Membrane Oxygenation (ECMO) Systems
  1. By Value
3. Paracorporeal Artificial Lungs
  1. By Value
4. Intracorporeal Artificial Lungs
  1. By Value
5. Membrane Oxygenators
  1. By Value
6. Portable Artificial Lungs
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Bridge-to-Transplantation
  1. By Value
3. Bridge-to-Recovery
  1. By Value
4. ECMO-assisted Ventilation
  1. By Value
5. Pulmonary Rehabilitation
  1. By Value
6. Long-term Support for Chronic Lung Diseases
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital-based Procurement
  1. By Value
3. Direct Tenders and Contracts
  1. By Value
4. Group Purchasing Organizations (GPOs)
  1. By Value
5. Online Procurement Platforms (limited role)
  1. By Value
6. Third-party Distributors (emerging in select regions)
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Tertiary Care Hospitals
  1. By Value
3. Transplant Centers
  1. By Value
4. Cardiac and Pulmonary ICUs
  1. By Value
5. Research Institutions and Clinical Trial Sites
  1. By Value
6. Specialty Respiratory Clinics
  1. By Value
U.S.
1. By Product Type
  1. Introduction
    1. Product Type By Value
  2. Extracorporeal Membrane Oxygenation (ECMO) Systems
    1. By Value
  3. Paracorporeal Artificial Lungs
    1. By Value
  4. Intracorporeal Artificial Lungs
    1. By Value
  5. Membrane Oxygenators
    1. By Value
  6. Portable Artificial Lungs
    1. By Value
2. By Application
  1. Introduction
    1. Application By Value
  2. Bridge-to-Transplantation
    1. By Value
  3. Bridge-to-Recovery
    1. By Value
  4. ECMO-assisted Ventilation
    1. By Value
  5. Pulmonary Rehabilitation
    1. By Value
  6. Long-term Support for Chronic Lung Diseases
    1. By Value
3. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital-based Procurement
    1. By Value
  3. Direct Tenders and Contracts
    1. By Value
  4. Group Purchasing Organizations (GPOs)
    1. By Value
  5. Online Procurement Platforms (limited role)
    1. By Value
  6. Third-party Distributors (emerging in select regions)
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Tertiary Care Hospitals
    1. By Value
  3. Transplant Centers
    1. By Value
  4. Cardiac and Pulmonary ICUs
    1. By Value
  5. Research Institutions and Clinical Trial Sites
    1. By Value
  6. Specialty Respiratory Clinics
    1. By Value
Canada

Europe Market Analysis

Introduction
By Product Type
1. Introduction
  1. Product Type By Value
2. Extracorporeal Membrane Oxygenation (ECMO) Systems
  1. By Value
3. Paracorporeal Artificial Lungs
  1. By Value
4. Intracorporeal Artificial Lungs
  1. By Value
5. Membrane Oxygenators
  1. By Value
6. Portable Artificial Lungs
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Bridge-to-Transplantation
  1. By Value
3. Bridge-to-Recovery
  1. By Value
4. ECMO-assisted Ventilation
  1. By Value
5. Pulmonary Rehabilitation
  1. By Value
6. Long-term Support for Chronic Lung Diseases
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital-based Procurement
  1. By Value
3. Direct Tenders and Contracts
  1. By Value
4. Group Purchasing Organizations (GPOs)
  1. By Value
5. Online Procurement Platforms (limited role)
  1. By Value
6. Third-party Distributors (emerging in select regions)
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Tertiary Care Hospitals
  1. By Value
3. Transplant Centers
  1. By Value
4. Cardiac and Pulmonary ICUs
  1. By Value
5. Research Institutions and Clinical Trial Sites
  1. By Value
6. Specialty Respiratory Clinics
  1. By Value
U.K.
1. By Product Type
  1. Introduction
    1. Product Type By Value
  2. Extracorporeal Membrane Oxygenation (ECMO) Systems
    1. By Value
  3. Paracorporeal Artificial Lungs
    1. By Value
  4. Intracorporeal Artificial Lungs
    1. By Value
  5. Membrane Oxygenators
    1. By Value
  6. Portable Artificial Lungs
    1. By Value
2. By Application
  1. Introduction
    1. Application By Value
  2. Bridge-to-Transplantation
    1. By Value
  3. Bridge-to-Recovery
    1. By Value
  4. ECMO-assisted Ventilation
    1. By Value
  5. Pulmonary Rehabilitation
    1. By Value
  6. Long-term Support for Chronic Lung Diseases
    1. By Value
3. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital-based Procurement
    1. By Value
  3. Direct Tenders and Contracts
    1. By Value
  4. Group Purchasing Organizations (GPOs)
    1. By Value
  5. Online Procurement Platforms (limited role)
    1. By Value
  6. Third-party Distributors (emerging in select regions)
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Tertiary Care Hospitals
    1. By Value
  3. Transplant Centers
    1. By Value
  4. Cardiac and Pulmonary ICUs
    1. By Value
  5. Research Institutions and Clinical Trial Sites
    1. By Value
  6. Specialty Respiratory Clinics
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Product Type
1. Introduction
  1. Product Type By Value
2. Extracorporeal Membrane Oxygenation (ECMO) Systems
  1. By Value
3. Paracorporeal Artificial Lungs
  1. By Value
4. Intracorporeal Artificial Lungs
  1. By Value
5. Membrane Oxygenators
  1. By Value
6. Portable Artificial Lungs
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Bridge-to-Transplantation
  1. By Value
3. Bridge-to-Recovery
  1. By Value
4. ECMO-assisted Ventilation
  1. By Value
5. Pulmonary Rehabilitation
  1. By Value
6. Long-term Support for Chronic Lung Diseases
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital-based Procurement
  1. By Value
3. Direct Tenders and Contracts
  1. By Value
4. Group Purchasing Organizations (GPOs)
  1. By Value
5. Online Procurement Platforms (limited role)
  1. By Value
6. Third-party Distributors (emerging in select regions)
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Tertiary Care Hospitals
  1. By Value
3. Transplant Centers
  1. By Value
4. Cardiac and Pulmonary ICUs
  1. By Value
5. Research Institutions and Clinical Trial Sites
  1. By Value
6. Specialty Respiratory Clinics
  1. By Value
China
1. By Product Type
  1. Introduction
    1. Product Type By Value
  2. Extracorporeal Membrane Oxygenation (ECMO) Systems
    1. By Value
  3. Paracorporeal Artificial Lungs
    1. By Value
  4. Intracorporeal Artificial Lungs
    1. By Value
  5. Membrane Oxygenators
    1. By Value
  6. Portable Artificial Lungs
    1. By Value
2. By Application
  1. Introduction
    1. Application By Value
  2. Bridge-to-Transplantation
    1. By Value
  3. Bridge-to-Recovery
    1. By Value
  4. ECMO-assisted Ventilation
    1. By Value
  5. Pulmonary Rehabilitation
    1. By Value
  6. Long-term Support for Chronic Lung Diseases
    1. By Value
3. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital-based Procurement
    1. By Value
  3. Direct Tenders and Contracts
    1. By Value
  4. Group Purchasing Organizations (GPOs)
    1. By Value
  5. Online Procurement Platforms (limited role)
    1. By Value
  6. Third-party Distributors (emerging in select regions)
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Tertiary Care Hospitals
    1. By Value
  3. Transplant Centers
    1. By Value
  4. Cardiac and Pulmonary ICUs
    1. By Value
  5. Research Institutions and Clinical Trial Sites
    1. By Value
  6. Specialty Respiratory Clinics
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Product Type
1. Introduction
  1. Product Type By Value
2. Extracorporeal Membrane Oxygenation (ECMO) Systems
  1. By Value
3. Paracorporeal Artificial Lungs
  1. By Value
4. Intracorporeal Artificial Lungs
  1. By Value
5. Membrane Oxygenators
  1. By Value
6. Portable Artificial Lungs
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Bridge-to-Transplantation
  1. By Value
3. Bridge-to-Recovery
  1. By Value
4. ECMO-assisted Ventilation
  1. By Value
5. Pulmonary Rehabilitation
  1. By Value
6. Long-term Support for Chronic Lung Diseases
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital-based Procurement
  1. By Value
3. Direct Tenders and Contracts
  1. By Value
4. Group Purchasing Organizations (GPOs)
  1. By Value
5. Online Procurement Platforms (limited role)
  1. By Value
6. Third-party Distributors (emerging in select regions)
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Tertiary Care Hospitals
  1. By Value
3. Transplant Centers
  1. By Value
4. Cardiac and Pulmonary ICUs
  1. By Value
5. Research Institutions and Clinical Trial Sites
  1. By Value
6. Specialty Respiratory Clinics
  1. By Value
UAE
1. By Product Type
  1. Introduction
    1. Product Type By Value
  2. Extracorporeal Membrane Oxygenation (ECMO) Systems
    1. By Value
  3. Paracorporeal Artificial Lungs
    1. By Value
  4. Intracorporeal Artificial Lungs
    1. By Value
  5. Membrane Oxygenators
    1. By Value
  6. Portable Artificial Lungs
    1. By Value
2. By Application
  1. Introduction
    1. Application By Value
  2. Bridge-to-Transplantation
    1. By Value
  3. Bridge-to-Recovery
    1. By Value
  4. ECMO-assisted Ventilation
    1. By Value
  5. Pulmonary Rehabilitation
    1. By Value
  6. Long-term Support for Chronic Lung Diseases
    1. By Value
3. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital-based Procurement
    1. By Value
  3. Direct Tenders and Contracts
    1. By Value
  4. Group Purchasing Organizations (GPOs)
    1. By Value
  5. Online Procurement Platforms (limited role)
    1. By Value
  6. Third-party Distributors (emerging in select regions)
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Tertiary Care Hospitals
    1. By Value
  3. Transplant Centers
    1. By Value
  4. Cardiac and Pulmonary ICUs
    1. By Value
  5. Research Institutions and Clinical Trial Sites
    1. By Value
  6. Specialty Respiratory Clinics
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Product Type
1. Introduction
  1. Product Type By Value
2. Extracorporeal Membrane Oxygenation (ECMO) Systems
  1. By Value
3. Paracorporeal Artificial Lungs
  1. By Value
4. Intracorporeal Artificial Lungs
  1. By Value
5. Membrane Oxygenators
  1. By Value
6. Portable Artificial Lungs
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Bridge-to-Transplantation
  1. By Value
3. Bridge-to-Recovery
  1. By Value
4. ECMO-assisted Ventilation
  1. By Value
5. Pulmonary Rehabilitation
  1. By Value
6. Long-term Support for Chronic Lung Diseases
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital-based Procurement
  1. By Value
3. Direct Tenders and Contracts
  1. By Value
4. Group Purchasing Organizations (GPOs)
  1. By Value
5. Online Procurement Platforms (limited role)
  1. By Value
6. Third-party Distributors (emerging in select regions)
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Tertiary Care Hospitals
  1. By Value
3. Transplant Centers
  1. By Value
4. Cardiac and Pulmonary ICUs
  1. By Value
5. Research Institutions and Clinical Trial Sites
  1. By Value
6. Specialty Respiratory Clinics
  1. By Value
Brazil
1. By Product Type
  1. Introduction
    1. Product Type By Value
  2. Extracorporeal Membrane Oxygenation (ECMO) Systems
    1. By Value
  3. Paracorporeal Artificial Lungs
    1. By Value
  4. Intracorporeal Artificial Lungs
    1. By Value
  5. Membrane Oxygenators
    1. By Value
  6. Portable Artificial Lungs
    1. By Value
2. By Application
  1. Introduction
    1. Application By Value
  2. Bridge-to-Transplantation
    1. By Value
  3. Bridge-to-Recovery
    1. By Value
  4. ECMO-assisted Ventilation
    1. By Value
  5. Pulmonary Rehabilitation
    1. By Value
  6. Long-term Support for Chronic Lung Diseases
    1. By Value
3. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital-based Procurement
    1. By Value
  3. Direct Tenders and Contracts
    1. By Value
  4. Group Purchasing Organizations (GPOs)
    1. By Value
  5. Online Procurement Platforms (limited role)
    1. By Value
  6. Third-party Distributors (emerging in select regions)
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Tertiary Care Hospitals
    1. By Value
  3. Transplant Centers
    1. By Value
  4. Cardiac and Pulmonary ICUs
    1. By Value
  5. Research Institutions and Clinical Trial Sites
    1. By Value
  6. Specialty Respiratory Clinics
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Artificial Lung Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Getinge AB
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Xenios AG (Fresenius Medical Care)
Medtronic plc
Abbott Laboratories
Abiomed (Johnson and Johnson MedTech)
LivaNova PLC
MicroPort Scientific Corporation
ALung Technologies, Inc.
Novalung GmbH (a Xenios company)
Nipro Corporation
Hemovent GmbH
Braile Biomédica
MC3 Cardiopulmonary

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment